Lee Ainslie’s Vertex Pharmaceuticals VRTX Stock Holding History

Lee Ainslie’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-812	Closed	-$330K	–	554
2023 Q4	$330K	Sell	812 -645	-44%	-$238K	0.01%	257
2023 Q3	$507K	Buy	+1,457	New	+$510K	0.01%	177
2021 Q4	–	Sell	-18,052	Closed	-$3.27M	–	624
2021 Q3	$3.27M	Buy	+18,052	New	+$3.52M	0.03%	127
2021 Q2	–	Sell	-6,254	Closed	-$1.34M	–	859
2021 Q1	$1.34M	Buy	+6,254	New	+$1.37M	0.01%	202
2020 Q2	–	Sell	-460	Closed	-$109K	–	682
2020 Q1	$109K	Buy	+460	New	+$106K	﹤0.01%	435
2015 Q2	–	Sell	-524,867	Closed	-$61.9M	–	133
2015 Q1	$61.9M	Buy	+524,867	New	+$62.9M	1%	31

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Lee Ainslie's VRTX Position: Q1 2024 in Review

Lee Ainslie sold out of Vertex Pharmaceuticals (VRTX) in Q1 2024, closing a stake of 812 shares — an estimated $330K sold.

Lee Ainslie first reported a position in VRTX in Q1 2015 and held it in 6 quarters. The position peaked at $61.9M in Q1 2015. 1,495 funds tracked by Wall St. Rank hold VRTX as of Q1 2024.

Lee Ainslie reported no remaining Vertex Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Lee Ainslie sold 812 Vertex Pharmaceuticals shares in Q1 2024, an estimated $330K.
Lee Ainslie first reported a position in Vertex Pharmaceuticals in Q1 2015 and held it in 6 quarters.
Lee Ainslie's Vertex Pharmaceuticals position peaked at $61.9M in Q1 2015.
1,495 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2024.

Based on Maverick Capital's 13F filing for Q1 2024, filed 15 May 2024.